The autoreactive antibodies continue to bind self-antigen on capillaries endothelial cells and leads to ongoing muscle destruction and skin inflammation as a consequence. A novel therapy for this disease and other humoral-based autoimmune diseases is the removal of B lymphocytes from the circulation by the action of an anti-CD20 monoclonal antibody (Rituximab).